Subscribe: pubmed: 0161-5505
Added By: Feedage Forager Feedage Grade C rated
Language: English
brain  fndp  glioblastoma  imaging  mice  microenvironment  pet imaging  pet  remodeling  seh  tumor  uptake  vascular microenvironment  vascular 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: pubmed: 0161-5505

pubmed: 0161-5505

NCBI: db=pubmed; Term=0161-5505


18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.
(image) Related Articles

18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.

J Nucl Med. 2016 Nov;57(11):1817-1822

Authors: Horti AG, Wang Y, Minn I, Lan X, Wang J, Koehler RC, Alkayed NJ, Dannals RF, Pomper MG

Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located within cytosol and peroxisomes that converts epoxides to the corresponding diols and hydrolyzes phosphate monoesters. It serves to inactivate epoxyeicosatrienoic acids (EETs), which are generated in the brain to couple neuronal activity and cerebral blood flow in normal and pathologic states. Altered regulation of sEH was observed previously in various neuropathologic disorders including vascular dementia and stroke. Inhibitors of sEH are pursued as agents to mitigate neuronal damage after stroke. We developed N-(3,3-diphenylpropyl)-6-(18)F-fluoronicotinamide ((18)F-FNDP), which proved highly specific for imaging of sEH in the mouse and nonhuman primate brain with PET.
METHODS: (18)F-FNDP was synthesized from the corresponding bromo precursor. sEH inhibitory activity of (18)F-FNDP was measured using an sEH inhibitor screening assay kit. Biodistribution was undertaken in CD-1 mice. Binding specificity was assayed in CD-1 and sEH knock-out mice and Papio anubis (baboon) through pretreatment with an sEH inhibitor to block sEH binding. Dynamic PET imaging with arterial blood sampling was performed in 3 baboons, with regional tracer binding quantified using distribution volume. The metabolism of (18)F-FNDP in baboons was assessed using high-performance liquid chromatography.
RESULTS: (18)F-FNDP (inhibition binding affinity constant, 1.73 nM) was prepared in 1 step in a radiochemical yield of 14% ± 7%, specific radioactivity in the range of 888-3,774 GBq/μmol, and a radiochemical purity greater than 99% using an automatic radiosynthesis module. The time of preparation was about 75 min. In CD-1 mice, regional uptake followed the pattern of striatum > cortex > hippocampus > cerebellum, consistent with the known brain distribution of sEH, with 5.2% injected dose per gram of tissue at peak uptake. Blockade of 80%-90% was demonstrated in all brain regions. Minimal radiotracer uptake was present in sEH knock-out mice. PET baboon brain distribution paralleled that seen in mouse, with a marked blockade (95%) noted in all regions indicating sEH-mediated uptake of (18)F-FNDP. Two hydrophilic metabolites were identified, with 20% parent compound present at 90 min after injection in baboon plasma.
CONCLUSION: (18)F-FNDP can be synthesized in suitable radiochemical yield and high specific radioactivity and purity. In vivo imaging experiments demonstrated that (18)F-FNDP targeted sEH in murine and nonhuman primate brain specifically. (18)F-FNDP is a promising PET radiotracer likely to be useful for understanding the role of sEH in a variety of conditions affecting the central nervous system.

PMID: 27417650 [PubMed - indexed for MEDLINE]

Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.
(image) Related Articles

Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.

J Nucl Med. 2016 Nov;57(11):1771-1777

Authors: Behling K, Maguire WF, Di Gialleonardo V, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR

Tumors escape antiangiogenic therapy by activation of proangiogenic signaling pathways. Bevacizumab is approved for the treatment of recurrent glioblastoma, but patients inevitably develop resistance to this angiogenic inhibitor. We previously investigated targeted α-particle therapy with (225)Ac-E4G10 as an antivascular approach and showed increased survival and tumor control in a high-grade transgenic orthotopic glioblastoma model. Here, we investigated changes in tumor vascular morphology and functionality caused by (225)Ac-E4G10.
METHODS: We investigated remodeling of the tumor microenvironment in transgenic Ntva glioblastoma mice using a therapeutic 7.4-kBq dose of (225)Ac-E4G10. Immunofluorescence and immunohistochemical analyses imaged morphologic changes in the tumor blood-brain barrier microenvironment. Multicolor flow cytometry quantified the endothelial progenitor cell population in the bone marrow. Diffusion-weighted MR imaged functional changes in the tumor vascular network.
RESULTS: The mechanism of drug action is a combination of remodeling of the glioblastoma vascular microenvironment, relief of edema, and depletion of regulatory T and endothelial progenitor cells. The primary remodeling event is the reduction of both endothelial and perivascular cell populations. Tumor-associated edema and necrosis were lessened, resulting in increased perfusion and reduced diffusion. Pharmacologic uptake of dasatinib into tumor was enhanced after α-particle therapy.
CONCLUSION: Targeted antivascular α-particle radiation remodels the glioblastoma vascular microenvironment via a multimodal mechanism of action and provides insight into the vascular architecture of platelet-derived growth factor-driven glioblastoma.

PMID: 27261519 [PubMed - indexed for MEDLINE]